![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Alecensa (alectinib) is an ALK tyrosine kinase receptor inhibitor, which is under phase 3 clinical trials for postoperative adjuvant therapy for ALK fusion gene-positive non-small cell lung cancer.
Lead Product(s): Alectinib Hydrochloride
Therapeutic Area: Oncology Product Name: Alecensa
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2024
Details:
Under the license agreement between Roche and Chugai, Chugai obtained commercialization rights in Japan for ALN-AGT01 (zilebesiran), an RNAi therapeutic targeting angiotensinogen, for hypertension with high cardiovascular risk.
Lead Product(s): Zilebesiran
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ALN-AGT01
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 19, 2024
Details:
Vabysmo (faricimab) is a vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) inhibitor, which is being evaluated for the treatment of angioid streaks associated with neovascularization.
Lead Product(s): Faricimab
Therapeutic Area: Ophthalmology Product Name: Vabysmo
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2024
Details:
Truqap (capivasertib) is a first-in-class, potent, adenosine triphosphate (ATP)-competitive inhibitor of all three AKT isoforms (AKT1/2/3), is approved in combination with Faslodex (fulvestrant) for the treatment of advanced HER2-/HR+ breast cancer.
Lead Product(s): Capivasertib,Fulvestrant
Therapeutic Area: Oncology Product Name: Truqap
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2024
Details:
Mitchga (nemolizumab) is an anti-IL-31 receptor A humanized monoclonal antibody, which is approved for the treatment of atopic dermatitis and prurigo nodularis.
Lead Product(s): Nemolizumab
Therapeutic Area: Dermatology Product Name: Mitchga
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Maruho
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Details:
Piasky (crovalimab) is a humanized complement inhibitor C5 monoclonal antibody. It is being developed for the treatment of adults and adolescents (12 years of age and above) with Paroxysmal Nocturnal Hemoglobinuria.
Lead Product(s): Crovalimab
Therapeutic Area: Rare Diseases and Disorders Product Name: Piasky
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Details:
Vabysmo (faricimab) is a vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) inhibitor indicated for the treatment of macular edema associated with retinal vein occlusion.
Lead Product(s): Faricimab
Therapeutic Area: Ophthalmology Product Name: Vabysmo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Details:
Enspryng (satralizumab-mwge) is an IL-6 receptor antagonist, currently being evaluated in the phase III clinical trial studies with patients for the treatment of Generalized Myasthenia Gravis.
Lead Product(s): Satralizumab
Therapeutic Area: Immunology Product Name: Enspryng
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2024
Details:
Lunsumio (mosunetuzumab) is a CD20xCD3 T cell-engaging bispecific antibody designed to target CD20 on B cells and CD3 on T cells. It is being evaluated for the treatment of relapsed and refractory follicular lymphoma.
Lead Product(s): Mosunetuzumab
Therapeutic Area: Oncology Product Name: Lunsumio
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2024
Details:
Tecentriq (atezolizumab) is a USFDA approved programmed death-ligand 1 (PD-L1) blocking antibody. It is being evaluated for the treatment of alveolar soft part sarcoma, an ultra-rare disease.
Lead Product(s): Atezolizumab
Therapeutic Area: Oncology Product Name: Tecentriq
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2024